Annual Benefit Report — FY1 (Aug 8, 2025 – Aug 7, 2026)

Confidentiality Level	
Date	09/11/2026
Date Created	November 9, 2026
Final Destination	Corporate Documents + sovereignlife.ca (public) + records office
Notes	Approved Nov 9, 2026.
# Revision	1
Signed By	Christopher Shewchuk
Status	Passed

Reporting period: August 8, 2025 to August 7, 2026 (first financial year)
Company: Sovereign Life Sciences Inc., a benefit company under the *Business Corporations Act* (British Columbia), BC1551977
Third-party standard: B Lab B Impact Assessment (Impact Topic Requirements)
Approved by the directors: November 9, 2026

1. About this report

This report is published under the *Business Corporations Act* (British Columbia), which requires a benefit company to report each year on how it carried out its commitment to conduct business in a responsible and sustainable manner and to promote the public benefits set out in its articles.

It covers the company's first financial year. During that year Sovereign was a pre-seed, pre-revenue company with one director, no employees, and no premises. Its work consisted of early research on *Justicia gendarussa* as a non-hormonal,

reversible male contraceptive, building scientific and advisory relationships, and setting up governance.

2. Benefit provision

On June 12, 2026, the directors and shareholders approved an amended benefit provision that consolidated the company's public benefits into the six commitments below, and the articles were restated on June 24, 2026. This report addresses the amended provision.

As a British Columbia Benefit Company, Sovereign Life Sciences Inc. commits to conducting its business in a responsible and sustainable manner and to promoting the following public benefits:

1. **Ethical, regenerative product development.** Developing health and wellness products through methods that respect all life, promote wellbeing, and favour natural, whole-plant approaches wherever sound.
2. **Scientific rigour informed by traditional knowledge.** Grounding our research in rigorous science while honouring the traditional knowledge systems and the relationships between people, plants, and place from which our work originates.
3. **Equitable partnership with source communities.** Partnering with knowledge-keepers and source communities through fair, transparent benefit-sharing, and supporting the cultural and linguistic vitality of the communities we work with.
4. **Equitable global access.** Making the benefits of our research accessible at scalable price points to people across all economic circumstances, including in the developing world.
5. **Cooperative, win-win enterprise.** Operating through a cooperative rather than extractive model, seeking outcomes that benefit shareholders, communities, ecosystems, and the planet.
6. **Relational wealth.** Fostering healthy, vibrant, and deeply supportive relationships of every kind (intimate, familial, communal, and professional) and advancing education and awareness that helps people build them.

3. How the company carried out its commitments

Responsible and sustainable business conduct

- Operated remotely with no premises. The main environmental footprint was research-related air travel.
- Adopted plain-English governance practice: each resolution carries a plain-English summary, and superseded records are kept and linked rather than deleted.
- After year-end, in October 2026, ratified organizational matters and confirmed the terms of the convertible notes and founder loan by directors' resolution, so that the company's records match its actual arrangements.
- Funded through the founder and convertible notes from two individual investors. No institutional capital was taken on terms that would conflict with the benefit provision.

1. Ethical, regenerative product development

- Focused the programme on a whole-plant source with documented traditional use, rather than a synthetic compound.
- Assessed cultivation sites in Costa Rica. The Caribbean lowlands were selected as the preferred region partly because of lower ecological risk, and cultivation is planned to reduce reliance on wild harvest. Cultivation will only proceed once an authenticated reference batch confirms the chemotype matches the source material.

2. Scientific rigour informed by traditional knowledge

- Funded and co-designed exploratory research with the Instituto Clodomiro Picado, University of Costa Rica. A proteomics study on whole semen was completed, and a second study designed to resolve a limitation of the first is in analysis.
- Treated the central mechanistic question (how the plant's active compounds produce their effect) as an open scientific question, and designed the next proposed study to answer it directly, not to confirm a preferred result.

- Began preparing a preclinical efficacy study proposal with an academic pharmacologist for submission to a non-profit funder.
- Credited the traditional knowledge of the Nimboran people of Jayapura Regency, Papua, as the origin of the work in all research and partner materials.

3. Equitable partnership with source communities

- Adopted an Indonesia Engagement Strategy (April 2026) that sets conditions before any commercial use:
  - Nimboran traditional-knowledge rights are recognized regardless of where plant material is grown.
  - Free, prior and informed consent and a co-developed benefit-sharing agreement are required before commercial use.
  - Alternative sourcing will be used if working through state channels risks harm to the community.
- Started outreach to an academic and community liaison in Jayapura. No agreement with the community exists yet; this is the most important open item under this commitment.

4. Equitable global access

- No product exists yet. The commitment shaped early strategy: an oral, plant-based product is intended to be lower-cost to produce and distribute than hormonal or device-based alternatives. No pricing decisions were made during the year.

5. Cooperative, win-win enterprise

- Worked with the Male Contraceptive Initiative (a non-profit funder), university researchers in Costa Rica and the United States, and pro bono strategic, operational and scientific advisors to advance non-hormonal male contraception.
- Structured research relationships as collaborations, with the company funding the work.

6. Relational wealth

- The company's core product aims to give couples a shared, non-hormonal contraceptive option, spreading the responsibility for contraception more evenly between partners.

4. Assessment against the third-party standard

Standard used

The directors selected the **B Impact Assessment** published by B Lab, using its Impact Topic Requirements (B Lab standards in effect in 2026). The assessment was completed as an internal self-assessment on October 16, 2026, using the company's online B Impact account. Results are a Year 0 baseline. They have not been verified by B Lab, and the company is not currently seeking B Corp Certification, so the Foundation Requirements were reviewed but not completed.

Results

Status as recorded in the assessment on October 16, 2026:

Topic	Requirement	Status	Summary
Purpose and Stakeholder Governance	PSG 1.1 Public purpose	In progress	Purpose is set out in the benefit provision, approved by directors and shareholders. Not yet published on the company website.
	PSG 2.1 Stakeholder mechanism	In progress	Directors are legally required to consider stakeholder interests; the Indonesia Engagement Strategy makes community consent a precondition. No formal stakeholder body yet.
	PSG 3.1 Grievance procedure	Not met	No public grievance procedure.
Justice, Equity, Diversity and Inclusion	JEDI 2.1 / 2.a Public JEDI commitment	In progress	Equity commitments exist in the benefit provision. A standalone public JEDI statement has not been published.

Topic	Requirement	Status	Summary
Human Rights	HR 4.2 Human rights in procurement	In progress	Sourcing conditions are set in the Indonesia Engagement Strategy. No formal supplier screening process yet.
Climate Action	CA 2.1 Climate action plan	Not met	No public climate plan. Footprint is small but includes research air travel.
Environmental Stewardship and Circularity	ESC 5.1 Environmental impacts in procurement	In progress	Ecological risk was a factor in cultivation site selection. No formal environmental procurement criteria.
Government Affairs and Collective Action	GACA 1.1 Responsible lobbying policy	Not met	The company does not lobby but has no written policy.
	GACA 2.1 Collective action (via 2.1b and 2.1c)	In progress	Met in substance through funded external research (2.1b) and multi-stakeholder collaboration (2.1c). Supporting evidence not yet attached.

Summary: Of the nine requirements assessed, none is fully met. Six are in progress, mostly because the practice exists but has not yet been written down, published or evidenced. Three are not met. Most gaps can be closed by publishing short statements on the company website.

Since the assessment: on October 16, 2026, after year-end, the company published its Purpose, Concerns and Grievances procedure, Equity Commitment, Climate commitment and Political Engagement policy on sovereignlife.ca. These address PSG 1.1, PSG 3.1, JEDI 2.a, CA 2.1 and GACA 1.1. On November 9, 2026, the assessment was updated to record these five requirements as met, with the published pages as evidence.

Plan for the next financial year

1. Attach evidence to GACA 2.1b and 2.1c (study summaries, collaboration records).
2. Write basic sourcing criteria covering human rights and environmental impact.

3. Set up a stakeholder input mechanism, starting with the Nimboran community relationship.
4. Re-run the assessment as Year 1 before the next report.

5. Circumstances that hindered the company

- **Capital.** The company raised a fraction of its first-phase funding target, which limited the pace of research and the time available for governance and publication work.
- **Institutional partners in Indonesia.** Engagement through university channels in Indonesia was unreliable during the year, which delayed progress toward a direct relationship with the source community.
- **Plant material supply.** A shipment of plant material to Costa Rica did not arrive, and import routes to Canada require phytosanitary documentation that has not yet been obtained.
- **Capacity.** With one director and no staff, compliance and research work competed for the same time. This report was published after the target date as a result.

6. Selection of the third-party standard

Process and rationale

The directors considered the standard during the year and chose the B Impact Assessment because:

- it is the most widely used framework for assessing a company's overall social and environmental performance, and it is free to use;
- it covers both overall responsible conduct and specific impact areas (governance, equity, human rights, climate, environment, collective action) that map to the company's public benefits;
- it can be used before revenue or staff, and scales as the company grows; and
- results can be compared year over year and, if the company later seeks certification, verified by B Lab.

This is the first year the company has selected a standard, so no change of standard took place.

Statements about the standard

- B Lab is a non-profit organization and is not related to the company. No director, officer or shareholder of the company, or any associate of one, is a member of B Lab's governing body or controls B Lab.
- B Lab publishes information about its governance, its funding and how its standards are developed:
  - Governance and team: bcorporation.net/en-us/movement/team
  - Standards development and governance: bcorporation.net/en-us/standards/development-and-governance
  - Funding: bcorporation.net/en-us/support-our-work

7. Approval

This benefit report was approved by the directors of Sovereign Life Sciences Inc. on November 9, 2026.

Christopher John Shewchuk, Director 

A copy of this report is available on the company's website and at its registered and records office, where any person may inspect it free of charge.